Ryan Allway April 7th, 2022 Psychedelics, Top News Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate molecules Biocompatibility of drug-loaded medical device demonstrates cell-based safety at doses anticipated to be within therapeutic range Current... Read more
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
March 31, 2022
Ryan Allway March 31st, 2022 Psychedelics, Top News TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic... Read more
Revitalist Increases Clinic Count to 10 with the Acquisition of a Virginia Ketamine Clinic
March 29, 2022
Ryan Allway March 29th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, March 29, 2022–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that has it has entered into a definitive agreement (“Merger Agreement“) to acquire Alchemy Wellness (“Alchemy“) a... Read more
Psychedelic Pharmaceutical Startup Ninnion Announces Formation of World Renowned Scientific Advisory Board
March 28, 2022
Ryan Allway March 28th, 2022 Psychedelics, Top News Board members include industry pioneers Dr. Rick Strassman and Dr. Charles B Nemeroff AUSTIN, TX –News Direct– Ninnion Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics today announced the formation of its Scientific Advisory Board (SAB). The board... Read more
Real Brands Announces Entry to Medical Psychedelics Market, Partners with Marcu & Arora for Licensure, R&D
CBD March 24, 2022
Ryan Allway March 24th, 2022 Psychedelics, Top News Real Brands applying for DEA psychedelics licensure Psychedelics drugs market size is projected to reach $10.75 billion by 2027 Real Brands planning to leverage new clinical research to produce and deliver safe, nature-based psychedelics product formulations that will effectively treat mental... Read more
Ryan Allway March 18th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British... Read more
Nova Mentis Announces Closing of Non-Brokered Financing
March 15, 2022
Ryan Allway March 15th, 2022 Psychedelics, Top News VANCOUVER, BC, March 15, 2022 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has completed a non-brokered private... Read more
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
March 14, 2022
Ryan Allway March 14th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today... Read more
PharmAla Biotech adds David Purcell as Director of Sales
March 14, 2022
Purcell to Accelerate PharmAla’s GMP MDMA Manufacturing and Sales Business VANCOUVER, BC, March 14, 2022 /CNW/ – In order to better serve its clinical trial customers, PharmAla Biotech Holdings Inc. (CSE: MDMA) is pleased to announce the hiring of Mr. David Purcell as Director of Sales. As a seasoned... Read more
Ryan Allway March 4th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, March 04, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”), has entered into an agreement with the... Read more
